Introduction Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age and is characterized by hormonal, biochemical, and metabolic abnormalities. 1 Recently, bisphenol A (BPA), a monomer widely used in the production of polycarbonate and epoxy resins and as an additive in polyvinyl chloride, 2 was linked to the pathogenesis of PCOS.
3 In terms of its mechanism of action, BPA can interact with both estrogen and androgen receptors.
3
Vitamin D deficiency has also been shown to be highly prevalent in women with PCOS 4 and to contribute to the etiology of the syndrome; however, the results are controversial. 1 To evaluate vitamin D metabolism and deficiency, serum vitamin D-binding protein (VDBP) levels should be determined, because this parameter affects free and bioavailable 25 -hydroxyvitamin D [25(OH)D] levels. 5 VDBP is secreted by the liver along with other proteins (eg, sex hormone-binding globulin [SHBG] ). It has also been suggested that VDBP is a biochemical predictor of liver fibrosis.
6
Recently, negative correlations have been found between serum levels of 25(OH)D and BPA in humans, 7 but the effect of serum BPA levels on VDBP concentrations in women with PCOS has not been assessed. In this pilot study, we aimed to determine the relationships between serum VDBP, vitamin D, SHBG, and BPA levels in women with PCOS.
Patients and methods A total of 63 women were recruited from among patients of the Department of Endocrinology, Diabetology and Isotope
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Bisphenol A levels are negatively correlated with serum vitamin D-binding protein and sex hormone-binding globulin levels in women with polycystic ovary syndrome: a pilot study using the Pearson product -moment correlation (for data with normal distribution) or the Spearman rank -order correlation (for data that did not pass the normality test). The results were considered significant at a P value of less than 0.05.
Results Both groups were similar in terms of age, body mass index, and waist circumference (TABLE 1). Women with PCOS presented significantly higher mean serum total testosterone and androstenedione levels as well as FAI value, but lower serum SHBG levels, than controls. Serum BPA, VDBP, and 25(OH)D levels as well as the frequency of vitamin D deficiency (<20 ng/ml) were comparable between groups. In contrast to the control group, woman with PCOS showed a negative correlation between serum BPA and VDBP levels (r = -0.46; P = 0.02) and SHBG levels (r = -0.46; P = 0.02). We found no correlation between serum BPA and 25(OH)D levels in either group.
To explain the differences in the association between serum BPA concentrations and liver proteins (VDBP and SHBG) in women with PCOS and the control group, we also measured the concentrations of liver biomarkers (AST, ALT, ALP, and GGT) and bilirubin. Serum bilirubin levels and the AST/ALT ratio were significantly higher in women with PCOS than in controls (TABLE 1) . Also, bilirubin levels correlated positively with BPA in the PCOS group (r = Plus ci4100 (Abbott Diagnostics, Lake Forrest, Illinois, United States).
Free androgen index (FAI) was calculated using the following formula: FAI = serum total testosterone concentration (nmol/l) × 100/SHBG (nmol/l). The AST/ALT ratio was also calculated.
Serum BPA concentrations were assessed using high -performance liquid chromatography with tandem mass spectrometry at the Department of Analytical Chemistry, Gdańsk University of Technology, Poland. A Shimadzu LCMS--8050 triple quadrupole mass spectrometer (Shimadzu, Kyoto, Japan) equipped with an electrospray ionization source working in the negative multiple reaction monitoring mode was used for the analysis. The method was described in detail elsewhere. 8 The study was performed in accordance with the guidelines of the 1964 Declaration of Helsinki on human experimentation and with approval of the local ethics committee. Informed consent was obtained from all participants.
The data were analyzed using the STATISTI-CA 12.0 package (StatSoft Polska, Kraków, Poland). The Shapiro-Wilk test was used for distribution analysis. Differences in clinical parameters between the groups were assessed with the unpaired t test or the nonparametric Mann-Whitney test. Associations between serum BPA levels and VDBP and 25(OH)D levels, as well as between serum BPA and liver biomarkers, were analyzed Our preliminary study has some limitations, including the small number of participants and no information about duration of exposure to BPA in either group. Another limitation is that all studied women were of normal weight, which prevented our assessment of the effect of BPA on obesity. The strengths of our pilot study include the very precise and sensitive method for BPA estimation.
8 Moreover, this is the first study to show the associations between serum VDBP and BPA levels in women with PCOS, as well as bilirubin and BPA in women with PCOS and healthy controls.
In summary, to our knowledge, this is the first study to show the association between serum VDBP, SHBG, and BPA levels in nonobese women with PCOS compared with healthy controls. Our findings require further research in a larger cohort of women with PCOS and different body weights. OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 4.0 International License (CC BY -NC -SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl. 0.45, P = 0.02), controls (r = 0.35, P = 0.046), and the whole study group (r = 0.42, P = 0.001). There were no correlations between VDBP and SHBG concentrations and any liver biomarkers.
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Discussion
The data on serum BPA levels in women with PCOS are limited and controversial. In our study, we found comparable serum BPA levels in women with PCOS and healthy controls matched for age and body mass index. Our data are in contrast with the findings of another study, which showed a higher serum BPA concentration in adolescents and adult women with PCOS compared with nonobese healthy controls.
9 Nonetheless, it is difficult to compare the results of these studies because of the different patient ethnicities, study protocols, biological material collected, and methods used to assess BPA levels.
The role of vitamin D in PCOS is still controversial. Some studies have shown a close association between 25(OH)D deficiency and negative metabolic consequences in women with PCOS, but others have reported similar serum levels of vitamin D in women with PCOS and controls.
4,10 In our study, we found comparable levels of serum 25(OH)D in women with PCOS and healthy controls and a relatively large number of cases with vitamin D deficiency (26% of women with PCOS vs 19% of women in the control group). Our observation is supported by recent data from the Netherlands. 4 Serum VDBP levels in both groups were comparable, but we found a significant negative correlation between serum VDBP, SHBG, and BPA levels only in women with PCOS.
Because VDBP was discovered as a novel biomarker in liver fibrosis (hepatic metabolism), 6 we explored the relationship between serum BPA concentrations and the levels of liver biomarkers and bilirubin. In our study, serum BPA did not correlate with liver enzymes, but there was a significant correlation between serum BPA and bilirubin levels in women with PCOS and the control group. Our results are not in line with previous observations in women with PCOS by Tarantino et al, 11 who reported that serum BPA levels correlated with liver enzymes; bilirubin levels were not determined in their study.
In our preliminary study, we found for the first time a significant relationship between serum BPA and bilirubin levels in women with PCOS. Until now, the cumulative hepatotoxicity of BPA was presented only in rats by dose -dependent increases in serum biochemical markers, ALT, ALP, and bilirubin. 12 We postulate that bilirubin levels can be the most sensitive marker of early liver dysfunction associated with exposure to BPA. The higher AST/ALT ratio in women with PCOS supported this concept, which requires further investigations. On this basis, we hypothesize that the different relationships between VDBP and BPA in women with PCOS in comparison with controls can be explained by liver dysfunction.
